Enanta is a clinical stage biotechnology company dedicated to creating oral drugs with an emphasis on indications in virology and immunology. Our story began in 1995 when we grew from humble beginnings to the company we are today — one that collaborated with AbbVie to discover two protease inhibitor compounds that were each developed and commercialized as part of an AbbVie combination regimen for chronic hepatitis C virus infection (glecaprevir in MAVYRET® and paritaprevir in VIEKIRA PAK®). We have also developed clinical candidates in nonalcoholic steatohepatitis, hepatitis B virus and SARS-CoV-2. Currently, our research and development programs are focused on respiratory syncytial virus and chronic spontaneous urticaria.
From our CEO
Enanta Pharmaceuticals is driven to develop best-in-class oral therapies that profoundly improve patients’ lives. We are focused on discovering novel drugs by leveraging proven methods grounded in medicinal chemistry, molecular biology and pharmacology. Through scientific excellence and imagination, we leverage our expertise in small molecule drugs to discover and develop groundbreaking medicines. Our vision is clear: we aim to transform the lives of patients with curative therapies.
Our previous success includes the discovery and development of two protease inhibitor compounds through our collaboration with AbbVie, which are sold as part of AbbVie’s combination regimens for chronic hepatitis C virus. These two regimens, which have been marketed under the trade names VIEKIRA PAK® and MAVYRET®, have helped cure over one million patients. We now work in other disease areas on treatments for patients where there is a significant high unmet need. Our areas of focus include virology and immunology.
At Enanta, we are working to have scientific innovation make a meaningful difference for patients suffering from serious viral infections and immunological diseases.
Jay R. Luly, Ph.D.
President, Chief Executive Officer and Director